title: The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant breast disease.
abstract: The role of the tumour marker CA-50 has been studied in the differential diagnosis of benign and malignant breast disease. Serum levels of CA-50 were determined by radioimmunoassay using a level of 17 units/ml as a cut-off. All 50 normal subjects and 22 of 24 patients (92%) with benign breast disease had CA-50 levels below 17 units/ml. By contrast, 15 of 36 patients (42%) with breast carcinoma had serum CA-50 levels above 17 units/ml (P less than 0.001). There was no clear correlation with tumour stage. The data suggest that CA-50 levels may help to differentiate benign and malignant diseases of the breast.
authors.affiliation: Department of Surgery, Royal Postgraduate Medical School, London.
authors.forename: M J
authors.initials: MJ
authors.lastname: Hershman
authors.forename: N A
authors.initials: NA
authors.lastname: Habib
authors.forename: S B
authors.initials: SB
authors.lastname: Kelly
authors.forename: J
authors.initials: J
authors.lastname: Beynon
authors.forename: R C
authors.initials: RC
authors.lastname: Williamson
authors.forename: P W
authors.initials: PW
authors.lastname: Davies
authors.forename: C B
authors.initials: CB
authors.lastname: Wood
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D001941:Breast Diseases / Q000175:diagnosis*; D001943:Breast Neoplasms / Q000175:diagnosis*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008875:Middle Aged; D011863:Radioimmunoassay
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate